ArticleInflammation2014
Protective effects of Lactobacillus plantarum NDC 75017 against lipopolysaccharide-induced liver injury in mice.
Article in Inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Effectiveness of Probiotics and Prebiotics Against Acute Liver Injury: A Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Lactobacillaceae in Acute and Chronic Liver Diseases: From Microbiota Modulation to Therapeutic Potential.Probiotics and antimicrobial proteins · 2026Review
- Article
- Article
- Synergistic effect of arginine andIranian journal of basic medical sciences · 2023Article
- Article
- Host miRNA-21 promotes liver dysfunction by targeting small intestinalGut microbes · 2020Article
- Lactobacillus plantarum C88 protects against aflatoxin BBMC microbiology · 2019Article
- Ammonium glycyrrhizin counteracts liver injury caused by lipopolysaccharide/amoxicillin-clavulanate potassium.Oncotarget · 2017Article
- Doses Lactobacillus reuteri depend on adhesive ability to modulate the intestinal immune response and metabolism in mice challenged with lipopolysaccharide.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the protective effect of Lactobacillus plantarum NDC 75017 (L. plantarum NDC 75017) against acute liver injury induced by lipopolysaccharide (LPS). Thirty male mice were randomly divided into the control, LPS, and LPS + L. plantarum NDC 75017 groups. In the LPS + L. plantarum group, the mice were orally pretreated with L. plantarum NDC 75017 for 15 days. At 16 days, the mice in the LPS and LPS + L. plantarum NDC 75017 groups were intraperitoneally injected with LPS at 4 mg/kg body weight, whereas the control mice were treated with an equal amount of saline. After 8 h, the serum alanine transaminase (ALT), aspartate aminotransferase (AST), and histology changes were examined. The oxidative stress markers and pro-inflammatory cytokines in the liver were also examined. Meanwhile, the expression of nuclear factor κB (NF-κB) mRNA and toll-like receptor 4 (TLR4) in the liver was determined by qRT-PCR. The LPS group showed an increase in ALT and AST, whereas the LPS + L. plantarum NDC 75017 group showed a significant decrease. In addition, pretreatment with L. plantarum NDC 75017 can attenuate LPS-induced oxidative stress and inflammatory response. Furthermore, the increase of hepatic NF-κB and TLR4 mRNA induced by LPS was significantly downregulated by the pretreatment with L. plantarum NDC 75017. These data show that pretreatment with L. plantarum NDC 75017 protects against LPS-induced oxidative stress and inflammatory injury in the liver of mice, which may be attributed to the inhibition of the TLR4-NF-κB pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.